Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
BLTE
BLTE
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BLTE News
Virtual Investor Conference Presentations Now Available Online
Apr 29 2026
Globenewswire
Deutsche Bank to Host Depositary Receipts Investor Conference
Apr 23 2026
Globenewswire
Belite Bio to Present at Investor Conference
Apr 22 2026
Globenewswire
Belite Bio to Present at Virtual Investor Conference
Apr 22 2026
Newsfilter
Belite Bio Initiates NDA Submission for Tinlarebant to Treat Stargardt Disease
Apr 22 2026
NASDAQ.COM
Insider at Belite Bio (BLTE.US) Plans to Sell $24.31 Million in Common Stock via Form 144
Apr 09 2026
moomoo
Insider at Belite Bio (BLTE.US) Plans to Sell $17.87 Million in Common Stock via Form 144
Apr 09 2026
moomoo
Belite Bio Reports $77.6M Net Loss for FY 2025
Mar 31 2026
seekingalpha
Belite Bio (BLTE) Q4 2025 Earnings Call Transcript
Mar 03 2026
NASDAQ.COM
Belite Bio Reports Q4 2025 Earnings Highlights
Mar 03 2026
seekingalpha
Belite Bio Reports Q4 Non-GAAP EPS Beat Expectations
Mar 02 2026
seekingalpha
Belite Bio Completes Enrollment in DRAGON II Trial for Stargardt Disease
Jan 27 2026
NASDAQ.COM
Latest Wall Street Ratings Overview
Jan 26 2026
CNBC
Wall Street Analysts Adjust Ratings on Key Stocks
Jan 26 2026
Benzinga
Morgan Stanley Initiates Belite Bio at Overweight with $191 Price Target
Jan 06 2026
CNBC
The $100 Club - Did You Get in Early on the Triple-Digit Surge of ABVX, NUTX, BLTE…?
Dec 19 2025
NASDAQ.COM
Show More News
